| Name | Title | Contact Details |
|---|
VeriTeQ's core technology evolved from implantable radio frequency identification (RFID) microchip technology used in the health care community for over two decades. This first-of-its-kind implantable RFID technology was cleared for use by the FDA in 2004 as a Class II medical device, originally to identify at-risk patients at the point of care. It has now evolved to help medical device manufacturers meet mandatory regulations outlined in the FDA's Safety & Innovation Act, signed into law in July 2012, and the FDA's Unique Device Identification (UDI) Final Rule. This technology is VeriTeQ's Q Inside Safety Technology. VeriTeQ's dosimeter technologies are used in the oncology suite and give an oncology team the ability to measure the dosage of radiation delivered to a patient on a per treatment basis. The data collected from our dosimeter technologies is invaluable when recording the total amount of radiation that a patient is exposed to during the entire treatment regimen, and the data can be used on a generic basis to develop future treatment regimens and evidence-based healthcare. VeriTeQ is developing an informatics and data analytics platform that will improve the type of medical device and treatment regimen data that can be used in many applications to improve patient healthcare and outcomes. Such examples include using VeriTeQ's UDI data in supply chain management for medical device manufacturers and healthcare institutions, quality and reimbursement controls for hospitals, and treatment regimen data for patients receiving chemotherapy and radiation therapy. VeriTeQ owns a rich portfolio of intellectual property protecting all of its current and future technologies.
Lucira Health has developed an at home COVID-19 test kit that delivers PCR quality molecular accuracy in the palm of your hand in 30 minutes or less. Our technology is transforming how we reduce the spread of infectious diseases by bringing accurate, easy-to-use self-testing into the home. This home test kit has not been FDA cleared or approved. This home test kit has been authorized by FDA under EUA. This home test kit has been authorized only for the testing of nasal swabs for detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This home test kit is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of IVDs for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or revoked sooner.
Sirtex is a rapidly growing, profitable, global life-sciences business focused on helping medical professionals improve clinical outcomes for cancer patients through innovative and effective interventional oncology therapies.
Mobile Aspects is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Shared PET imagining is a Canton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.